SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial

BACKGROUND: BGB-DXP593, a neutralising monoclonal antibody against SARS-CoV-2, has demonstrated strong activity in reducing viral RNA copy number in SARS-CoV-2-infected animal models. We aimed to examine the efficacy and safety of BGB-DXP593 in ambulatory patients with mild-to-moderate COVID-19. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Vega, Ramses, Antila, Martti, Perez, Carlos, Mookadam, Mohamed, Xie, Fangjie, Zhang, Wei, Rizwan, Ahsan, Yao, Zhen, Rasko, John E.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933486/
https://www.ncbi.nlm.nih.gov/pubmed/36820098
http://dx.doi.org/10.1016/j.eclinm.2023.101832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933486/
https://www.ncbi.nlm.nih.gov/pubmed/36820098
http://dx.doi.org/10.1016/j.eclinm.2023.101832

Ejemplares similares